MDGL NASDAQ
Madrigal Pharmaceuticals, Inc.
1W: -2.1%
1M: -15.3%
3M: -18.8%
YTD: -26.3%
1Y: +3.3%
3Y: +235.9%
5Y: +425.9%
$440.33
+2.59 (+0.59%)
After Hours: $455.06 (+14.73, +3.35%)
Weekly Expected Move ±4.1%
$399
$416
$434
$452
$470
Credit Risk of going bust: lower than 79% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.39 (down 99.7%), Madrigal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $347.8M against a stock market value of $10.11B.
Distance to default 9.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $171.4M (short-term plus half of long-term), stock volatility 43.5%; Altman Z'' -2.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.39 (down 99.7%), Madrigal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $347.8M against a stock market value of $10.11B.
Distance to default 9.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $171.4M (short-term plus half of long-term), stock volatility 43.5%; Altman Z'' -2.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-12-23
Earliest Filing
2026-01-30
Latest Filing
partner: 3
Counterparties (Filed by MDGL)
3 relationshipsCompanies named in MDGL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd | — | partner | Partner in Research, Development, and Commercialization Agreement for Rezdiffra | 2026-01-30 | View |
| Hoffmann-La Roche Inc | — | partner | Partner in Research, Development, and Commercialization Agreement for Rezdiffra | 2026-01-30 | View |
| Cowen and Company, LLC | — | partner | Sales agent for the ATM Program. | 2022-12-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-06-17 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-04-28 | Officer/Director Change | View | |
| 2026-02-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-22 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2025-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-17 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-11 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR